Cat. No. 4926
Chemical Name: (1S,2S)-2-(3,4-Dichlorobenzoyl)cycl
Biological ActivityPotent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (IC50 = 20 nM). Increases kynurenic acid levels, and decreases 3-HK and QUIN levels in cerebrum and liver of neonatal rodents. Neuroprotective in a Drosophila model of Huntington's disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Amaral et al (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496 382. PMID: 23575632.
Campesan et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr.Biol. 21 961. PMID: 21636279.
Amori et al (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J.Neurochem. 109 316. PMID: 19226371.
Ceresoli-Borroni et al (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J.Neurosci.Res. 85 845. PMID: 17279543.
If you know of a relevant reference for UPF 648 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses UPF 648 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: UPF 648, supplier, UPF648, potent, kynurenine, 3-monooxygenase, 3-hydroxylase, KMO, inhibitors, inhibits, huntington's, disease, KYNA, 3-hk, QUIN, neuroprotective, Tocris Bioscience, Hydroxylase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Fluorometric CYP450 substrateGaleterone
CYP17 inhibitor; also androgen receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.